Xcell Therapeutics, Inc.

As of June 30, 2026, Xcell Therapeutics, Inc. carries a market capitalization of 20.77B, placing it among publicly traded companies globally. Its enterprise value stands at 21.93B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Xcell Therapeutics, Inc. has 17.29M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 4.23, and the price-to-book ratio stands at 4.80.

These figures are as of June 30, 2026. The EV/Sales ratio of 5.03 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 21.93B versus a market cap of 20.77B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Xcell Therapeutics, Inc. maintains a current ratio of 1.28, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 124.44, indicating elevated leverage, while an interest coverage ratio of 74.49 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Xcell Therapeutics, Inc. posted a negative return on equity (ROE) of -271.41, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -91.92, reflecting losses generated across the asset base. The company generates approximately 66.26M in revenue per employee across its workforce of 65.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.23 indicates how many times Xcell Therapeutics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Xcell Therapeutics, Inc. recorded an income tax benefit of -65.48M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -11.43B and -11.37B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Xcell Therapeutics, Inc.'s stock has declined approximately 54.71% over the past 52 weeks. The 50-day moving average sits at 1,116.48, while the 200-day moving average is 1,362.93.

Over the twelve months ended June 30, 2026, Xcell Therapeutics, Inc. generated 4.36B in revenue and converted that into -11.37B in net income, yielding earnings per share of -740.96. EBITDA reached -9.66B, while operating income came in at -11.30B.

As of June 30, 2026, Xcell Therapeutics, Inc. holds 4.23B in cash and equivalents against 5.38B in total debt, resulting in a net debt position of 645.67M. Total book value stands at 4.33B, with working capital of 1.44B providing operational flexibility.

Xcell Therapeutics, Inc. produced -10.56B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -328.61M in capital expenditures, free cash flow totaled -10.89B - equivalent to -710.00 per share.

Over the twelve months ended June 30, 2026, Xcell Therapeutics, Inc. posted a gross margin of -43.16, reflecting its pricing power and cost economics. The operating margin of -259.36 and net profit margin of -260.88 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -59.12: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -41.20, meaning Xcell Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Xcell Therapeutics, Inc.'s most recent stock split took place on October 1, 2025 with a 553:628 split ratio.

As of June 30, 2026, Xcell Therapeutics, Inc. has an Altman Z-Score of -9.31, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.